MX392945B - Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. - Google Patents

Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Info

Publication number
MX392945B
MX392945B MX2019013537A MX2019013537A MX392945B MX 392945 B MX392945 B MX 392945B MX 2019013537 A MX2019013537 A MX 2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A MX 392945 B MX392945 B MX 392945B
Authority
MX
Mexico
Prior art keywords
compounds
diseases
prevention
treatment
aspects
Prior art date
Application number
MX2019013537A
Other languages
English (en)
Other versions
MX2019013537A (es
Inventor
Eliezer Zomer
Joseph M Johnson
Peter G Traber
Raphael Nir
Ryan George
Sharon Shechter
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of MX2019013537A publication Critical patent/MX2019013537A/es
Publication of MX392945B publication Critical patent/MX392945B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Algunos aspectos de la invención se relacionan con compuestos sintéticos novedosos que tienen afinidad de enlace con las proteínas de galectina.
MX2019013537A 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. MX392945B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (2)

Publication Number Publication Date
MX2019013537A MX2019013537A (es) 2020-02-13
MX392945B true MX392945B (es) 2025-03-19

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013537A MX392945B (es) 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Country Status (12)

Country Link
US (2) US11576924B2 (es)
EP (1) EP3621973A4 (es)
JP (1) JP7204676B2 (es)
KR (1) KR102626669B1 (es)
CN (1) CN110869378B (es)
AU (1) AU2018265571B2 (es)
BR (1) BR112019023722A2 (es)
CA (1) CA3062648A1 (es)
IL (1) IL270469B2 (es)
MX (1) MX392945B (es)
WO (1) WO2018209255A1 (es)
ZA (1) ZA201908165B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275718B2 (en) 2018-12-06 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP7547345B2 (ja) * 2018-12-27 2024-09-09 グリコミメティクス， インコーポレイテッド ガレクチン－３阻害性ｃ－グリコシド
EP3947407B1 (en) 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR102890853B1 (ko) * 2019-04-10 2025-11-24 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114269737A (zh) 2019-08-15 2022-04-01 爱杜西亚药品有限公司 2-羟环烷-1-胺甲酰基衍生物
ES2972551T3 (es) 2019-08-29 2024-06-13 Idorsia Pharmaceuticals Ltd Derivados de alfa-D-galactopiranósido
CA3161794A1 (en) * 2019-12-24 2021-07-01 John L. Magnani Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
US12275720B2 (en) * 2020-05-05 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CN115551850A (zh) 2020-05-11 2022-12-30 百时美施贵宝公司 半乳凝素-3的小分子抑制剂
US12291522B2 (en) 2020-05-28 2025-05-06 Bristol-Myers Squibb Company Galectin-3 inhibitors
KR20230083301A (ko) * 2020-10-06 2023-06-09 이도르시아 파마슈티컬스 리미티드 알파-d-갈락토피라노사이드의 스피로 유도체
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
KR20230145111A (ko) * 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
KR20230154221A (ko) * 2021-03-03 2023-11-07 이도르시아 파마슈티컬스 리미티드 트리아졸릴-메틸 치환된 알파-d-갈락토피라노시드 유도체

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9626450D0 (en) * 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
GB0501008D0 (en) * 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
JP2010510223A (ja) 2006-11-15 2010-04-02 サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド Ｔｉｍ−３調節物質の治療的使用
WO2009139719A1 (en) 2008-05-16 2009-11-19 Forskarpatent I Syd Ab Novel synthesis of galactoside inhibitors
EP2424873B1 (en) 2009-04-28 2017-11-15 Galecto Biotech AB Novel galactoside inhibitors of galectins
JP5702386B2 (ja) 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
BR112014006220A2 (pt) 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
DK2797942T3 (en) 2011-12-28 2018-12-10 Galectin Therapeutics Inc Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
CA2884802A1 (en) * 2012-10-31 2014-05-08 Galecto Biotech Ab Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
US20170014446A1 (en) 2014-03-10 2017-01-19 La Jolla Pharmaceutical Company Compositions and methods for administering galectin antagonists
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2017019770A1 (en) 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
CN109071585B (zh) 2016-03-04 2022-08-16 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
WO2018209276A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Also Published As

Publication number Publication date
JP2020519625A (ja) 2020-07-02
KR20200016246A (ko) 2020-02-14
IL270469B1 (en) 2023-03-01
JP7204676B2 (ja) 2023-01-16
IL270469A (es) 2019-12-31
US11576924B2 (en) 2023-02-14
MX2019013537A (es) 2020-02-13
EP3621973A1 (en) 2020-03-18
BR112019023722A2 (pt) 2020-05-26
AU2018265571A1 (en) 2019-12-05
EP3621973A4 (en) 2021-10-27
KR102626669B1 (ko) 2024-01-17
ZA201908165B (en) 2023-07-26
US20200155586A1 (en) 2020-05-21
WO2018209255A1 (en) 2018-11-15
US20230132265A1 (en) 2023-04-27
IL270469B2 (en) 2023-07-01
CA3062648A1 (en) 2018-11-15
AU2018265571B2 (en) 2022-09-29
CN110869378B (zh) 2023-10-13
CN110869378A (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
MX392945B (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
MX394409B (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
MX2018003491A (es) Represores de htt y usos de estos.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
PE20170256A1 (es) Proteinas de union y sus metodos de uso
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
EA201891299A1 (ru) Терапевтические антитела к cd9
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2019003557A1 (es) Anticuerpos anti-trkb.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3858868A4 (en) POLYPEPTIDE COMPOSITION